| DB ID | MyCo_1118 |
| Title | (1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial |
| Year | 2022 |
| PMID | 35708758 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | Sepsis |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | The ethics board of the Jena University Hospital, the corresponding institutional review boards of all participating centers and the Federal Institute for Drugs and Medical Devices approved the trial. The trial was registered at ClinicalTrials. gov (NCT02734550). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Negative |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | 339 patients were enrolled in the study. |
| Cohort No. | 339 |
| Age Group | 58-78 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | BDG assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | BDG Assay |
| Up Regulation Down Regulation | Negative |
| Sequence Data | None |
| External Link | None |
